Lung Cancer Europe shared a post on LinkedIn:
“Lung cancer survival has more than doubled.
New real-world data from public hospitals in France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) – driven by earlier diagnosis and targeted treatment.
Median survival also increased, from 8.5 months to 20.7 months.
These aren’t trial results – this is real-world care, and it’s changing outcomes.
And while the data comes from France, it matters far beyond. It shows what’s possible when health systems deliver timely diagnosis, molecular testing, and access to the right treatment.
This is what progress looks like. But it must reach everyone who needs it.”
Title: Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
Authors: Didier Debieuvre, Lionel Falchero, Olivier Molinier, Sébastien Couraud, Alexis Cortot, Nicolas Meyer, Bernard Asselain, Etienne Auvray, Dorine Templement-Grangerat, Acya Bizieux, Jean Tredaniel, Sophie Schneider, Jean-Bernard Auliac, Olivier Bylicki, Alexia Letierce, Hugues Morel
You can read the Full Article on NEJM Evidence
More posts featuring Lung Cancer Europe.
